Nerve Growth Factor in Patients With Arterial Hypertension: Neuropsychical, Hemodynamic, Metabolic Relationships

Aim. To investigate the changes of serum nerve growth factor (NGF) level in patients with arterial hypertension (AH) and obesity in dependence on the degree of psycho-emotional stress and physical activity. Materials and methods. We examined 76 male patients with stage I and II AH with mean age 46.75±0.56 years (36 patients with and 40 without obesity). Control group consisted of 26 individuals without AH, obesity, and cardiovascular diseases. All patients underwent ambulatory blood pressure (BP) monitoring. Serum concentrations of NGF β-subunit and cortisol were determined by enzyme linked immunosorbent assay. For assessment of levels of psycho-emotional stress, reactive and personal anxiety, and physical activity we used Psychological Stress Measure (PSM-25), the Spielberger-Khanin questionnaire, and brief International Physical Activity Questionnaire (IPAQ), respectively. Results. Level of NGF in patients with AH and obesity (0.94±0.28 pg/ml) was higher than in non-obese patients with AH (0.21±0.06 pg/ml; p=0.018) with highest figures in patients with insufficient physical activity and high level of psycho-emotional stress. In all groups of patients there was unidirectional reverse correlation between serum NGF and cortisol levels. According to ambulatory BP monitoring, NGF level was inversely proportional to systolic and diastolic BP variability in patients with AH and obesity and in the control group. Reduced serum concentration of NGF was associated with increased levels of reactive and personal anxiety. Conclusion. Obtained data suggests that NGF plays an important role in complex multifactorial interactions between neuropsychic, cardiovascular and metabolic processes.

фактор роста нервов, артериальная гипертензия, ожирение, психоэмоциональное напряжение, nerve growth factor, arterial hypertension, obesity, psycho-emotional stress

1. Aloe L., Rocco M. L., Bianchi P., Manni L. Nerve growth factor: from the early discoveries to the potential clinical use. J Translational Med 2012; 10:239. doi: 10.1186/1479-5876-10-239.

2. Cirulli F., Alleva E. The NGF saga: from animal models of psychosocial stress to stress-related psychopathology. Front Neuroendocrinol 2009; (3):379-395. doi: 10.1016/j. yfrne. 2009.05.002.

3. Berry A., Bindocci E., Alleva E. NGF, Brain and Behavioral Plasticity. Neural Plasticity 2012;2012:784040. doi:10.1155/2012/784040. http://www.hindawi.com/ jourals / np/2012/784040/(07July 2016)

4. Aloe L., Tonchev A. B., Fiore M., Chaldakov G. N. Homo diabesus: involvement of metabotrophic factors. Adipobiology 2013;5:45-49.

5. Sopova K., Gatsiou K., Stellos K., Laske C. Dysregulation of neurotrophic and haematopoietic growth factors in Alzheimer's disease: from pathophysiology to novel treatment strategies. Curr Alzheimer Res 2014;11 (1):27-39.

6. Yanev S., Aloe L., Fiore M., Chaldakov G. N. Neurotrophic and metabotrophic potential of nerve growth factor and brain-derived neurotrophic factor: linking cardiometabolic and neuropsychiatric diseases. World J Pharmacol 2013;2:92-99. doi:10.5497/wjp. v2. i4.92

7. Alleva E., Santucci D. Psychosocial vs. “physical" stress situations in rodents and humans: role of neurotrophins. Physiol Behav 2001;73 (3):313-320.

8. Nikulina E. M., Johnston C. E., Wang J., Hammer R. P. Jr. Neurotrophins in the ventral tegmental area: Role in social stress, mood disorders and drug abuse. Neuroscience 2014;282C:122-138. doi:10.1016/j. neuroscience. 2014.05.028.

9. Chen Y. W., Lin P. Y., Tu K. Y. et al. Significantly lower nerve growth factor levels in patients with major depressive disorder than in healthy subjects: a meta-analysis and systematic review. Neuropsychiatr Dis Treat 2015;11:925-933. doi:10.2147/NDT. S81432.

10. Alleva E., Petruzzi S., Cirulli F., Aloe L. NGF regulatory role in stress and coping of rodents and humans. Pharmacol Biochem Behav 1996;54 (1):65-72.

11. Schulte-Herbrüggen O., Fuchs E., Abumaria N. et al. Effects of escitalopram on the regulation ofbrain-derived neurotrophic factor and nerve growth factor protein levels in a rat model of chronic stress. J Neurosci Res 2009;87 (11):2551-2560. doi:10.1002/jnr. 22080.

12. Aloe L., Alleva E., Fiore M. Stress and nerve growth factor: findings in animal models and humans. Pharmacol Biochem Behav 2002;73 (1):159-166.

13. Horowitz M. A., Zunszain P. A., Anacker C. et al. Glucocorticoids and inflammation: a double-headed sword in depression? How do neuroendocrine and inflammatory pathways interact during stress to contribute to the pathogenesis of depression? Mod Trends Pharmacopsychiatri 2013; (28):127-143.

14. Numakawa T., Adachi N., Richards M. et al. Brain-derived neurotrophic factor and glucocorticoids: reciprocal influence on the central nervous system. Neuroscience 2013;239:157-72. doi:10.1016/j. neuroscience. 2012.09.073.

15. Halade G. V., Ma Y., Ramirez T. A. et al. Reduced BDNF attenuates inflammation and angiogenesis to improve survival and cardiac function following myocardial infarction in mice. Am J Physiology - Heart and Circulatory Physiology 2013;305 (12):H1830 - H1842. doi: 10.1152/ajpheart. 00224.2013.

16. Hristova M. G. Metabolic syndrome and neurotrophins: effects of metformin and non-steroidal antiinflammatory drug treatment. Eurasian J Med 2011;43 (3):141-145. doi:10.5152/eajm. 2011.32.

17. Bullo M., Peeraully M. R., Trayhurn P. et al. Circulating nerve growth factor levels in relation to obesity and the metabolic syndrome in women. Eur J Endocrinol 2007;157 (3):303-310.

18. Chazova I. E., Ratova L. G., Boitsov S. A. et al. Recommendations for the management of arterial hypertension. Russian Medical Society of Arterial Hypertension and Society of Cardiology of the Russian Federation. Systemic Hypertension 2015;3:5-26.

19. Vodopianova N. E. Psychodiagnostics of stress. SPb: Piter 2009; р. 336. Russian (Водопьянова Н. Е. Психодиагностика стресса. СПб: Питер 2009; с. 336).

20. Khanin Yu. L. Manual for the State-Trait Anxiety Inventory by Spielberger CD. L: LNIIFK 1976; 18p.

21. Bubnova M. G., Aronov D. M., Boytsov S. A. Provision of physical activity in people with limitations in health. Moscow 2015; p. 95.

22. Schlaich M., Straznicky N., Lambert E., Lambert G. Metabolic syndrome: a sympathetic disease? Lancet Diabetes Endocrinol 2015;3 (2):148-157. doi: 10.1016/S2213-8587 (14) 70033-6.

23. Holmes M. E., Ekkekakis P., Eisenmann J. C. The physical activity, stress and metabolic syndrome triangle: a guide to unfamiliar territory for the obesity researcher. Obesity Rev 2010;11 (7):492-507. doi:10.1111/j. 1467-789X. 2009.00680. x.

24. Gentile C., Dragomir A., Solomon C. et. all. Sex differences in the prediction of metabolic burden from physiological responses to stress. Ann Behav Med 2015;49 (1):112-127. doi:10.1007/s12 160-014-9639-2.